Contezolid
- Generic Name
- Contezolid
- Indication
用于治疗由对本品敏感的金黄色葡荷球菌（甲氧西林敏感和耐药的菌株，包括MRSA）、化脓性链球菌或无乳链球菌引起的复杂性皮肤和软组织感染。
为减少细菌耐药的发生，确保康替唑胺及其他抗菌药物的疗效，本品应仅用于治疗已确诊或高度怀疑由敏感菌引起的感染。本品不适用于治疗革兰阴性菌感染。如确诊或怀疑合并有革兰阴性菌感染，建议联合应用抗革兰阴性菌药物进行治疗
MicuRx's MRX-4 Meets Primary Endpoint in Phase III cSSTI Trial
• MicuRx's MRX-4 for injection, transitioning to oral Contezolid, demonstrated non-inferiority to intravenous Linezolid in treating complex skin and soft tissue infections (cSSTI).
• The Phase III trial in China showed MRX-4/Contezolid had good clinical and microbiological efficacy, meeting the primary endpoint for cSSTI treatment.
• MRX-4/Contezolid exhibited a favorable safety profile, with a significantly lower incidence of platelet reduction compared to Linezolid.
• MicuRx plans to submit a New Drug Application (NDA) for MRX-4 in China and continue Phase III trials for drug-resistant Gram-positive bacteria and diabetic foot infections.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath